TScan Therapeutics announced workforce reductions of roughly 30% and the termination of a Phase I solid‑tumor T‑cell receptor program as the company refocuses resources on blood‑cancer indications. The move reflects strategic retrenchment after challenges advancing solid tumor TCR assets and follows wider sector pressure on small cell‑therapy companies to extend cash runway. Management framed the layoffs and trial halt as precision moves to conserve capital and prioritize higher‑value programs. The actions will accelerate pipeline pruning and may spur business development activity or asset divestitures for the affected solid‑tumor assets.